DS-3201b
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Acute
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Trial Timeline
Apr 5, 2017 → Mar 9, 2021
NCT ID
NCT03110354About DS-3201b
DS-3201b is a phase 1 stage product being developed by Daiichi Sankyo for Leukemia, Myeloid, Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT03110354. Target conditions include Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Acute were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04276662 | Phase 1 | Completed |
| NCT03110354 | Phase 1 | Terminated |
Competing Products
20 competing products in Leukemia, Myeloid, Acute